Document is current
Any future updates will be listed below
-
Authors
Crook, Peter https://orcid.org/0000-0002-9094-6558
Logan, Clare https://orcid.org/0000-0003-3037-8314
Mazzella, Andrea https://orcid.org/0000-0003-1560-7465
Wake, Rachel M. https://orcid.org/0000-0003-3193-4888
Cusinato, Martina https://orcid.org/0000-0002-5371-2314
Yau, Ting https://orcid.org/0000-0003-0558-0772
Ong, Yee-Ean
Planche, Timothy https://orcid.org/0000-0002-0263-0888
Basarab, Marina
Bicanic, Tihana https://orcid.org/0000-0002-2676-838X
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (ACF-2021-16-001, CL-2019-16-001)
Merck Sharp and Dohme (60408)
- License Information
-
More Information
Article History
Received: 2 July 2023
Accepted: 11 October 2023
First Online: 17 November 2023
Declarations
:
: The study was granted ethical approval by the Health Research Authority Health and Care Research Wales (HCRW), South Central—Oxford B Research Ethics Committee (REC reference: 20/SC/0220). Ethical approval was granted without the need for informed consent from participants as the study was using routinely collected clinical data. This research was carried out in accordance with the principles of the Declaration of Helsinki.
: Not applicable.
: TB has received speaker fees, advisory board fees and research fellowship funding from Gilead Sciences, advisory board fees from Mundipharma and research grants from Pfizer and MSD. CL has received conference sponsorship from Gilead Sciences UK. TY has received sponsorship and/or honorarium from Gilead Sciences, Pfizer, Astella Pharma, Renascience Pharma and Tillotts Pharma. All other authors have no interests to declare.
